IL297268A - Therapeutic use of pleuromutilins - Google Patents

Therapeutic use of pleuromutilins

Info

Publication number
IL297268A
IL297268A IL297268A IL29726822A IL297268A IL 297268 A IL297268 A IL 297268A IL 297268 A IL297268 A IL 297268A IL 29726822 A IL29726822 A IL 29726822A IL 297268 A IL297268 A IL 297268A
Authority
IL
Israel
Prior art keywords
hydroxy
mutilin
acetyl
cyclohexylsulfanyl
diastereomer
Prior art date
Application number
IL297268A
Other languages
English (en)
Hebrew (he)
Inventor
Hafner Michael
Paukner Susanne
Wicha Wolfgang
Riedl Rosemarie
IVEZIC-SCHOENFELD Zrinka
Original Assignee
Nabriva Therapeutics GmbH
Hafner Michael
Paukner Susanne
Wicha Wolfgang
Riedl Rosemarie
Zrinka Ivezic Schoenfeld
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabriva Therapeutics GmbH, Hafner Michael, Paukner Susanne, Wicha Wolfgang, Riedl Rosemarie, Zrinka Ivezic Schoenfeld filed Critical Nabriva Therapeutics GmbH
Publication of IL297268A publication Critical patent/IL297268A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
    • C07C321/16—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL297268A 2020-04-17 2021-04-16 Therapeutic use of pleuromutilins IL297268A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063011474P 2020-04-17 2020-04-17
EP20170072 2020-04-17
EP20183292 2020-06-30
PCT/EP2021/025140 WO2021209174A1 (en) 2020-04-17 2021-04-16 Therapeutic use of pleuromutilins

Publications (1)

Publication Number Publication Date
IL297268A true IL297268A (en) 2022-12-01

Family

ID=75801547

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297268A IL297268A (en) 2020-04-17 2021-04-16 Therapeutic use of pleuromutilins

Country Status (9)

Country Link
US (1) US20230174472A1 (https=)
EP (1) EP4135682A1 (https=)
JP (2) JP2023522644A (https=)
CN (1) CN115443131A (https=)
BR (1) BR112022020007A2 (https=)
CA (1) CA3180535A1 (https=)
IL (1) IL297268A (https=)
TW (1) TW202203908A (https=)
WO (1) WO2021209174A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250134844A1 (en) 2022-02-09 2025-05-01 Nabriva Therapeutics GmbH Therapeutic use of pleuromutilins
EP4338732A1 (en) 2022-09-16 2024-03-20 Nabriva Therapeutics GMBH Lefamulin and its derivatives for use in the treatment of tularemia
CN119925362A (zh) * 2023-11-03 2025-05-06 阳光安津(南京)生物医药科技有限公司 一种化合物在制备用于治疗银屑病的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298733B1 (en) * 2005-06-27 2016-05-25 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
GB0803707D0 (en) 2008-02-28 2008-04-09 Cambridge Entpr Ltd Antiviral agent
EP2399904A1 (en) * 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
CN103204787B (zh) 2012-01-17 2014-10-01 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
CN103242210B (zh) 2012-02-09 2014-09-24 北京艾百诺科技有限公司 含有取代方酸的乙酸妙林酯及其应用
KR102656841B1 (ko) 2015-06-17 2024-04-12 나브리바 테라퓨틱스 게엠베하 레파뮬린의 주사가능한 약제학적 제형
CN110507823B (zh) * 2019-08-20 2021-08-24 中国医学科学院基础医学研究所 衣康酸相关物质在诊断、防治病毒感染性疾病中的应用

Also Published As

Publication number Publication date
CA3180535A1 (en) 2021-10-21
JP2023522644A (ja) 2023-05-31
BR112022020007A2 (pt) 2022-11-22
WO2021209174A1 (en) 2021-10-21
EP4135682A1 (en) 2023-02-22
TW202203908A (zh) 2022-02-01
US20230174472A1 (en) 2023-06-08
CN115443131A (zh) 2022-12-06
JP2026041886A (ja) 2026-03-10

Similar Documents

Publication Publication Date Title
JP2026041886A (ja) プレウロムチリンの治療的使用
EP4135683B1 (en) Antiviral use of pleuromutilins
KR20150013527A (ko) 항염증 활성과 접합된 증진된 항인플루엔자제
CN115836079B (zh) 烟酰胺单核苷酸和烟酰胺核苷衍生物及其在治疗特别是由流感病毒或冠状病毒引起的病毒感染和呼吸道并发症中的用途
JP2020196704A (ja) インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤
US20220193073A1 (en) Method of treating fibrosis
CN118742310B (zh) 一种次黄碱衍化合物在制备治疗肺纤维化药物中的应用
US20230210848A1 (en) Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug
EP1660059A1 (en) Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome (sars)
CN115484953A (zh) 治疗细胞因子风暴综合症及相关疾病的方法
JP2003531866A (ja) 抗体を用いた呼吸器疾患の組合せ治療法
US20210322311A1 (en) Inhalable Formulation of a Solution Containing Tiotropium Bromide and Olodaterol
KR20220127823A (ko) 화합물 및 α1-항트립신 결핍의 치료를 위한 이의 용도
EP4135681B1 (en) Antiviral use of pleuromutilins
EP4125924B1 (en) Furosemide compositions for use in supportive therapy in coronavirus infection
US20230127198A1 (en) Compositions and methods for the treatment of toxic gas exposure
KR101002794B1 (ko) 이량체 화합물 및 항바이러스제로서의 그의 용도
JPH05310578A (ja) ミゾリビンを有効成分とする感染疾患の予防または治療剤
WO2025257398A1 (en) Dicarboxylic acids and esters thereof for use in the treatment of a viral lung infection
KR20240009157A (ko) 바이러스 감염증 치료용 약학 조성물 및 치료 방법
HK40076778B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
HK40076778A (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
CN110302157A (zh) 一种异丙托溴铵气雾剂组合物及其制备方法
KR20070031392A (ko) 스타틴과 기관지확장제와의 조합물
HK1053792B (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis